• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Duncan Buell

    3/10/25 5:42:02 PM ET
    $POCI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $POCI alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Duncan Buell

    (Last) (First) (Middle)
    C/O PRECISION OPTICS CORPORATION, INC.
    22 EAST BROADWAY

    (Street)
    GARDNER MA 01440

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    02/28/2025
    3. Issuer Name and Ticker or Trading Symbol
    PRECISION OPTICS CORPORATION, INC. [ POCI ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Joseph N. Forkey 03/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $POCI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $POCI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $POCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Woodward Peter H exercised 30,000 shares at a strike of $2.19 and covered exercise/tax liability with 14,536 shares (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      5/20/25 4:15:06 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Pellegrino Joseph P Jr

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      3/21/25 4:17:04 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Forkey Joseph Norman was granted 20,000 shares, increasing direct ownership by 16% to 142,572 units (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      3/21/25 4:15:13 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Precision Optics Corporation Inc.

      SC 13G/A - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

      11/13/24 5:53:45 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Precision Optics Corporation Inc.

      SC 13G - PRECISION OPTICS CORPORATION, INC. (0000867840) (Subject)

      5/17/24 5:03:18 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    SEC Filings

    See more
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/23/25 4:40:06 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/20/25 4:15:10 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - PRECISION OPTICS CORPORATION, INC. (0000867840) (Filer)

      5/19/25 4:30:09 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Coll Wayne M bought $107,905,271 worth of shares (4,317 units at $24,995.43) (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:31 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Executive Officer Forkey Joseph Norman bought $17,228,869 worth of shares (1,725 units at $9,987.75), increasing direct ownership by 1% to 122,572 units (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:30 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Lawande Mahesh bought $17,248,850 worth of shares (1,726 units at $9,993.54) (SEC Form 4)

      4 - PRECISION OPTICS CORPORATION, INC. (0000867840) (Issuer)

      8/16/24 4:30:33 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Precision Optics Reports Third Quarter Fiscal Year 2025 Financial Results

      GARDNER, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its third quarter fiscal year 2025 for the period ended March 31, 2025. Q3 2025 Financial Highlights (3 Months Ended March 31, 2025): Revenue was $4.2 million compared to $5.2 million in the same quarter of the previous fiscal year and compared to $4.5 million in the most recent sequential quarter.Production revenue was $3.3 million compared to $3.0 million in the same quarter of the previous fiscal year and compared to $

      5/15/25 4:30:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

      GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

      5/8/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

      GARDNER, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025, at 4:00 p.m. Pacific Time (7:00 p.m. Eastern Time). Dr. Joe Forkey, Chief Executive Officer of Precision Optics, will be hosting the presentation and answering questions at the conclusion. To access the live presentation, please use the following information: Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapCl

      4/21/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Financials

    Live finance-specific insights

    See more
    • Precision Optics Schedules Third Quarter of Fiscal Year 2025 Conference Call for May 15, 2025

      GARDNER, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's third quarter fiscal year 2025 financial results on Thursday, May 15, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, May 15, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, May 15, 2025, at 5:00 p.m. ET. Call-in Information: Interested par

      5/8/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Schedules Second Quarter of Fiscal Year 2025 Conference Call for February 13, 2025

      GARDNER, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's second quarter fiscal year 2025 financial results on Thursday, February 13, 2025, at 5:00 p.m. ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, February 13, 2025, followed by the conference call. Conference Call Details Date and Time: Thursday, February 13, 2025, at 5:00 p.m. ET. Call-in Information: Inter

      2/11/25 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Corporation Schedules First Quarter of Fiscal Year 2025 Conference Call for November 14, 2024

      GARDNER, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it has scheduled a conference call to discuss the Company's first quarter fiscal year 2025 financial results on Thursday, November 14, 2024, at 5:00pm ET. The Company intends to release its financial results and to file its 10-Q after the close of the market on Thursday, November 14, 2024, followed by the conference call. Conference Call Details Date and Time: Thursday, November 14, 2024, at 5:00pm ET Call-in Information: Interested pa

      11/11/24 4:15:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $POCI
    Leadership Updates

    Live Leadership Updates

    See more
    • Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

      GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

      3/20/25 9:00:00 AM ET
      $LMAT
      $POCI
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
    • Precision Optics Appoints Buell Duncan to Board of Directors; Dr. Richard Miles Retires from Board

      GARDNER, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Buell Duncan to its Board of Directors. Mr. Duncan brings decades of executive leadership and strategic expertise, further strengthening the Company's commitment to innovation and growth. With an extensive career in the technology and business sectors, Mr. Duncan held senior leadership positions at a number of IBM global business units from 1992 through 2020 where he was instrumental in driving marketing, strategy, and business deve

      3/4/25 4:30:00 PM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Precision Optics Appoints Clay Schwabe as VP of Sales and Marketing

      GARDNER, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced the appointment of Clay Schwabe, as the Company's Vice President of Sales and Marketing. Mr. Schwabe has over fifteen years of experience in medical device market access, sales, sales management, global product marketing, and commercialization. He is an emerging technologies specialist with experience in early-stage commercialization of minimally invasive surgical products and procedures. Most recently, he served as VP Business Development, Commercial Strategy, CRO, an

      7/8/24 9:00:00 AM ET
      $POCI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care